Animal Or Plant Cell Patents (Class 424/93.7)
  • Patent number: 11345889
    Abstract: The present invention provides an artificial tissue culture comprising a heterogeneous population of cells of at least two different tissue sections, wherein said tissue sections are in a three dimensional structure, method of generating such a tissue and kits suitable for said method or maintain a three dimensional tissue culture.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: May 31, 2022
    Assignee: IMBA-Institut fur Molekulare Biotechnologie GMBH
    Inventors: Juergen Knoblich, Madeline A. Lancaster
  • Patent number: 11344577
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 31, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • Patent number: 11338292
    Abstract: A microfluidic particle sorting apparatus for capturing targets from fluid containing the targets is disclosed. The apparatus includes an inlet for receiving the fluid; a sorting chamber allowing the fluid to flow through; a first outlet for discharging the fluid after flowing through the sorting chamber; a capturing structure for capturing the cells, wherein the capturing structure is upstream of the first outlet, and includes obstacles in an array, each extending through the sorting chamber in a lateral direction with respect to a fluid flow of the fluid; and a second outlet upstream of the capturing structure comprising a plurality of openings; wherein a gap between two adjacent obstacles is equal to or greater than each opening of the second outlet.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: May 24, 2022
    Assignee: BOE Technology Group Co., Ltd.
    Inventors: Zhihong Wu, Defeng Mao, Zijian Zhao, Yudan Yin
  • Patent number: 11332715
    Abstract: Disclosed is a method for culturing mesenchymal stem cells, comprising culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition of 2 to 5% oxygen. The culturing method can increase the population of mesenchymal stem cells even with a small number of passages by improving mesenchymal stem cells in proliferative capacity and viability. In addition, the mesenchymal stem cells prepared by the culturing method are effectively used to treat or improve a pulmonary disease.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 17, 2022
    Assignee: MEDIPOST CO., LTD
    Inventors: Yoon-Sun Yang, Won Il Oh, Sun Jae Kwon, Mi Yeon Lee, Hong Bae Jeon
  • Patent number: 11324858
    Abstract: The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: May 10, 2022
    Assignees: The Trustees of the University of Pennsylvania, Massachusetts Institute of Technology
    Inventors: Christopher S. Chen, Jan D. Baranski, Ritika Chaturvedi, Michael T. Yang, Kelly R. Stevens, Sangeeta N. Bhatia
  • Patent number: 11324215
    Abstract: A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: May 10, 2022
    Assignee: Vivex Biologies Group, Inc.
    Inventors: Harry Thomas Temple, Timothy Ganey, Stephanie Gonzalez, Tracy Scott Anderson, Shabnam Namin
  • Patent number: 11318170
    Abstract: The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: May 3, 2022
    Assignee: StemCyte, Inc.
    Inventors: Shinn-Zong Lin, Woei-Cherng Shyu, Hung Li
  • Patent number: 11278042
    Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium an energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The energy modulation agent has a normal predominant emission of radiation in a first wavelength range outside of a second wavelength range (WR2) known to produce the change, but under exposure to the applied initiation energy produces the change. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: March 22, 2022
    Assignee: IMMUNOLIGHT, LLC
    Inventors: Frederic A. Bourke, Jr., Zakaryae Fathi, Harold Walder, Wayne F. Beyer, Jr.
  • Patent number: 11278710
    Abstract: Methods and devices related to the fields of skin care, hair restoration and lip care wherein the systems may be used by an individual for infusing treatment media into skin or lips for cosmetic and rejuvenation purposes, hair restoration purposes or other therapeutic purposes.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: March 22, 2022
    Assignee: Hermes Innovations, LLC
    Inventor: John H. Shadduck
  • Patent number: 11278574
    Abstract: The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.
    Type: Grant
    Filed: September 8, 2018
    Date of Patent: March 22, 2022
    Assignees: AVITA INTERNATIONAL LTD., FUNDAÇÂO BUTANTAN
    Inventors: Irina Kerkis, Cristiane Valverde Wenceslau
  • Patent number: 11274276
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: March 15, 2022
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Francis C. Zeigler, Mark Baumgartner, Kyle Nickey
  • Patent number: 11273179
    Abstract: The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34+ cells and CD3+ cells. In certain embodiments, the compositions include CD34+ cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 15, 2022
    Assignee: MEDEOR THERAPEUTICS, INC.
    Inventors: Steven R. Deitcher, Corinna X. Chen
  • Patent number: 11273193
    Abstract: The invention relates to a synergistic composition comprising a dry extract of plant of genus Galeopsis and a compound promoting autophagy selected from biotin and R-N1-spermidine or a salt thereof, wherein R is hydrogen or methyl and mixtures thereof. The synergistic compositions according to the invention may be in the form of a topical formulation or oral formulation and is useful as a promoter of autophagy especially in cells of human scalp hair follicles and in promoting hair growth and/or in the treatment of hair thinning or hair loss.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: March 15, 2022
    Assignee: GIULIANI S.P.A.
    Inventors: Giammaria Giuliani, Ralf Paus, Benedetto Grimaldi, Barbara Marzani, Sergio Baroni
  • Patent number: 11274280
    Abstract: The present invention relates to generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors. The present invention also relates to functional beta cells produced by said methods and uses of said beta cells.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Nicolaj Stroeyer Christophersen, Ulrik Doehn, Mattias Hansson
  • Patent number: 11261429
    Abstract: This invention relates to an enriched population of isolated and expanded human cord blood stem cells and a method of producing an enriched population of isolated and expanded human cord blood stem cells. The expanded human cord blood stem cells are CD34+, CD90+, CD1 84+, CD1 17+, CD49f+, ALDH+, CD45RA? and express pluripotency genes SOX2, OCT4, NANOG, and ZIC3. In one embodiment, the stem cells in the enriched population of the present invention are positive for aldehyde dehydrogenase activity (ALDH+). In addition, in one embodiment the expanded stem cells are nearly depleted of T cells and B cells and contain a limited number of monocytes (CD14). Also disclosed is a method of treating a subject for a hematological disorder using the stem cells of the present invention and a method of determining the effects of a compound on hematopoietic stem cells.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: March 1, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Pratima Chaurasia, Ronald Hoffman
  • Patent number: 11248211
    Abstract: The subject invention is directed to a composition comprising primed connective tissue cells and a pharmaceutically acceptable carrier thereof.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: February 15, 2022
    Assignee: KOLON TISSUEGENE, INC.
    Inventors: Moon Jong Noh, Youngsuk Yi, Kwan Hee Lee
  • Patent number: 11246994
    Abstract: Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided. Methods of treating a hand of a patient are also provided.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: February 15, 2022
    Assignee: LifeCell Corporation
    Inventors: Hui Xu, Hui Li, Ming F. Pomerleau, Darin Messina
  • Patent number: 11242503
    Abstract: A method for dissociating cell aggregates in an agitated reactor. The method comprises providing a cell culture comprising cell aggregates in the agitated reactor, contacting the cell aggregates with a dissociation reagent, generating a dissociation force in the agitated reactor and exposing the contacted cell aggregates to the generated dissociation force under conditions sufficient to dissociate the contacted cell aggregates. The method may be used in a process for passaging cells and/or generating dissociated differentiated cells from stem and/or progenitor cells.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: February 8, 2022
    Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Nicholas Timmins, Lesley Chan
  • Patent number: 11235005
    Abstract: This invention relates to a method for repairing and reconstructing a damaged or non-functional muscle, in particular to a method and a tool kit using in vitro primed motor endplate-expressing muscle progenitor cells (MPCs) to promote innervation of the damaged or non-functional muscle using an agent without any genetic manipulation. This method is particularly useful for repairing or reconstructing damaged or non-functional head and neck muscles, and urinary detrusor bladder muscle.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 1, 2022
    Assignee: Purdue Research Foundation
    Inventor: Stacey L. Halum
  • Patent number: 11236207
    Abstract: Analyte-insensitive materials comprising polymerizable monomers suitable for use in forming a hydrophilic, cross-linked gel comprising on the surface of a substrate for an electrode.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: February 1, 2022
    Inventors: Eric K. Lee, Boaz Vilozny, James Andrew
  • Patent number: 11236304
    Abstract: Disclosed are a method for preparing induced pluripotent stem cells from endocardium-derived adult stem cells isolated from peripheral blood and a method for differentiating induced pluripotent stem cells into cardiovascular cells. The endocardium-derived adult stem cells are primary culture cells for preparing induced pluripotent stem cells, can be readily isolated and cultured only with a small amount of peripheral blood, have a high proliferation property so as to be storable without generic variation, and can rapidly ensure a cell number so as to be usable in cell therapy. The endocardium-derived adult stem cells have sternness, thereby having high preparation efficiency, and are derived from the endocardium so as to have the epigenetic memory of cardiovascular cells, thereby having an advantage of being able to be differentiated, after preparing induced pluripotent stem cells, into cardiovascular cells such as endothelial cells, smooth muscle cells and cardiomyocytes with a high efficiency.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: February 1, 2022
    Assignee: SEOUL NATIONAL UNIVERSITY HOSPITAL
    Inventors: Hyo-Soo Kim, Han-Mo Yang, Ju-Young Kim, Joo-Eun Lee
  • Patent number: 11230700
    Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: January 25, 2022
    Assignee: ORBSEN THERAPEUTICS LIMITED
    Inventor: Stephen Joseph Elliman
  • Patent number: 11231355
    Abstract: A cell capture system including an array, an inlet manifold, and an outlet manifold. The array includes a plurality of parallel pores, each pore including a chamber and a pore channel, an inlet channel fluidly connected to the chambers of the pores; an outlet channel fluidly connected to the pore channels of the pores. The inlet manifold is fluidly connected to the inlet channel, and the outlet channel is fluidly connected to the outlet channel. A cell removal tool is also disclosed, wherein the cell removal tool is configured to remove a captured cell from a pore chamber.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 25, 2022
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Kalyan Handique
  • Patent number: 11225642
    Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 18, 2022
    Assignees: Kyoto University, Astellas Pharma Inc.
    Inventors: Kenji Osafune, Takafumi Toyohara, Yukiko Yamagishi
  • Patent number: 11214844
    Abstract: The invention herein provides biofabricated materials having zonal properties and methods of making biofabricated materials having zonal properties.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 4, 2022
    Assignee: Modern Meadow, Inc.
    Inventors: Brendan Patrick Purcell, Suzanne Lee, Lixin Dai, Katherine Amy Congdon, Stephen M. Spinella, Chi Man Ng
  • Patent number: 11214772
    Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: January 4, 2022
    Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Atsushi Kuwahara, Suguru Yamasaki, Yasushi Hiramine, Yoshiki Sasai, Masayo Takahashi
  • Patent number: 11198856
    Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: December 14, 2021
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat, Marine Beurdeley
  • Patent number: 11186819
    Abstract: Provided is a method of serum-free culturing corneal limbal stromal stem cells and inducing them to differentiate and form spheres. Also provide is a medium combination for inducing corneal limbal stromal stem cells to form spheres or differentiate into corneal limbal stromal cells in vitro. The serum-free medium combination used herein can provide sufficient nutrients and a good environment required for cell growth and proliferation, can provide a stable in vitro expansion of corneal limbal stromal stem cells and can ensure that the expanded corneal limbal stromal stem cells keep their stemness and specificity. In addition, a system for inducing them to differentiate into corneal limbal stromal cells is successfully built. It can be used in experimental studies of corneal limbal stromal stem cells, cell therapy of corneal lesions and transplant for corneal injury.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 30, 2021
    Assignee: ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY
    Inventors: Hong Ouyang, Liqiong Zhu
  • Patent number: 11186821
    Abstract: Provided is a method for inducing differentiation of neural crest cells into neurons of the autonomic nervous system, the method including the step of culturing neural crest cells in the presence of at least one of a BMP signaling pathway activator, an SHH signaling pathway inhibitor, and a Wnt signaling pathway inhibitor.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: November 30, 2021
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Yasuyuki Kida, Yuzo Takayama
  • Patent number: 11186826
    Abstract: An object of the present invention is to provide a cell population comprising mesenchymal cells having low cell aggregability, which is useful for intravenous administration of a cell preparation, and a method for producing the same, and a pharmaceutical composition comprising the cell population. Also provided are methods for producing a cell population comprising mesenchymal stem cells, the method comprising obtaining a cell population having the following cell characteristics (the cell population satisfies the relative expression level of COL11A1 gene to the expression level of SDHA gene of 6.0 or less and the relative expression level of COL16A1 gene to the expression level of SDHA gene of 1.5 or less).
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 30, 2021
    Assignee: KANEKA CORPORATION
    Inventors: Keita Ino, Yuta Kita
  • Patent number: 11180728
    Abstract: The present disclosure concerns an in-vitro full skin model which comprises a dermal equivalent and epidermal equivalent as well as from about 1 to about 100 three-dimensional sweat gland equivalents with respectively from about 500 to about 500000 sweat gland cells as well as a diameter of respectively from about 100 to about 6000 ?m on a supporting layer. Furthermore, the present disclosure concerns the production of the full skin model as well as the use of this model as an in-vitro model, in screening methods as well as for in-vitro evaluation of the influence of cosmetic substances on the inhibition of sweat secretion as well as body odor.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 23, 2021
    Assignee: HENKEL AG & CO. KGAA
    Inventors: Patricia Klaka, Sabine Gruedl, Melanie Giesen, Thomas Welss, Bernhard Banowski, Lars Vierkotten
  • Patent number: 11180733
    Abstract: The present disclosure provides a method of generating mature mesenchymal stem cells and the cell culture medium used in such method. Also disclosed herein include a mesenchymal stem cell culture obtained by the method as disclosed herein, and uses thereof.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: November 23, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Tong Ming Liu, Bing Lim, Pin Li
  • Patent number: 11178875
    Abstract: Methods for spray drying gram negative bacteria are provided. Such spray drying methods are performed under conditions that allow for the spray dried composition to retain the biological activity of interest of the gram-negative bacteria. Further provided are compositions comprising a spray dried gram-negative bacteria, where the spray dried formulation comprises at least 105 CFU/gram of said gram-negative bacteria. The gram-negative bacteria employed in the various methods and compositions can comprise a biological activity of interest which, in specific embodiments, controls one or more pathogens that cause plant disease and/or improve at least one agronomic trait of interest. The spray dried formulation can be used as an inoculant for plants. Methods for growing a plant susceptible to plant disease and methods and compositions for controlling plant disease are also provided. Further provided are methods and compositions of increasing disease resistance in plants.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 23, 2021
    Assignee: AgBiome, Inc.
    Inventors: Kyle Beery, Alexander P. Schlesinger, James D. Sievert, Kelly S. Smith
  • Patent number: 11168302
    Abstract: Provided are a method of preparing retinal ganglion cells by differentiation of stem into retinal ganglion cells, retinal ganglion cells differentiated by the method, a method of screening for a death inhibitor or a proliferation promoter of retinal ganglion cells using the retinal ganglion cells differentiated by the method, a kit of screening for the death inhibitor or the proliferation promoter of retinal ganglion cells including the retinal ganglion cells differentiated by the method, a pharmaceutical composition for treating glaucoma or optic neuropathy including the retinal ganglion cells, a method of treating glaucoma or optic neuropathy including the step of administering the retinal ganglion cells to a subject suspected of having glaucoma or optic neuropathy, and a method of preparing a mature retinal ganglion cell line.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: November 9, 2021
    Assignee: ClavisTherapeutics, INC.
    Inventors: Sung Sup Park, Ji Yeon Kim
  • Patent number: 11166907
    Abstract: The present invention provides a conductive hydrogel comprising a polystyrene sulfonate compound selected from poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), reduced graphene oxide polystyrene sulfonate (rGO:PSS) and rGO:PEDOT:PSS; and a conjugate of polyethylene glycol (PEG) and a linker-(BX)n oligopeptide of formula (I) PEG-linker-(BX)n??(I) wherein B is lysine or arginine, X is selected from alanine, glycine, serine, threonine, tyrosine, glutamic acid or aspartic acid and n is an integer selected from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20. The invention further relates to processes for assembling the conductive hydrogel. The conductive hydrogel can be used in various biomedical applications, such as neuroprostheses, biosensors, nerve grafts, cell culture and encapsulation of cells and microorganisms as well as for drug delivery.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: November 9, 2021
    Assignee: DENOVOMATRIX GMBH
    Inventors: Yixin Zhang, Yong Xu, Alvin Thomas
  • Patent number: 11160834
    Abstract: Preparations comprising an enriched population of extracellular vesicles (nEVs) having a negatively charged surface, and that are CD81+ and CD9?, are provided. Improved processes and methods for producing an enriched population of nEVs from non-murine cells, especially human origin cells and/or tissues, are disclosed. Therapeutic methods for using the preparations, including for reducing brain inflammation and treatment of various pathologies associated with brain inflammation, such as by intravenous or intranasal administration, are also described. Methods and preparations for reducing brain inflammation associated with traumatic brain injury (TBI) are also disclosed. A method for treating a patient having suffered a mild traumatic injury (mTMI), or concussion, such as a sports-related head injury, is also disclosed. The nEVs are also demonstrated to reduce the expression level of IL-I? in brain tissue of an animal having had traumatic brain injury.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: November 2, 2021
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Darwin J. Prockop, Dong-Ki Kim, Hidetaka Nishida, Askok K. Shetty
  • Patent number: 11161831
    Abstract: Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 2, 2021
    Assignee: Baylor College of Medicine
    Inventors: David J. Tweardy, Moses M. Kasembeli, Marvin X. Xu, Thomas Kristian Eckols
  • Patent number: 11160292
    Abstract: An protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol and/or other spirits serving as an entertaining and novel non-beverage method of consuming alcohol. The article of manufacture encapsulates ethyl alcohol and/or other spirits in the amorphous regions of the complex macromolecular structure releasing it only upon chewing and exposure to the environment of the oral cavity. The article of manufacture is stable and capable of retaining shape and form for extended periods of time at ambient temperature allowing for relatively low-cost commercial manufacture and distribution.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: November 2, 2021
    Assignee: Cure Pharmaceutical Holding Corp.
    Inventors: Margaret Teresa Thomas Virgallito, Joshua Alan Held
  • Patent number: 11149248
    Abstract: A three dimensional cell culture and bioreactor system is provided. The system comprises one or more cell culture chamber. Each cell culture chamber comprises an inlet port and an outlet port in fluid communication with the cell culture chamber. The cell culture chambers may be segregated or in fluid communication with one another. The systems may be used to conduct drug efficacy test, isolate certain cell types from a complex tissue sample of multiple cell types, allow for the ex vivo culturing of patient tissue samples to help guide the course of treatment, and conduct co-culture experiments.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: October 19, 2021
    Assignee: Kiyatec, Inc.
    Inventors: Matthew R. Gevaert, David E. Orr, Hal Crosswell
  • Patent number: 11147840
    Abstract: A Muscular Dystrophy Chimeric Cell generated by ex vivo fusion of a myoblast with a second myoblast, mesenchymal stem cell, or stromal cell is described as is the use of the same in the treatment of a muscular dystrophy.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 19, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Maria Siemionow
  • Patent number: 11141455
    Abstract: The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: October 12, 2021
    Assignee: TXP Pharma GmbH
    Inventor: Thomas Boesen
  • Patent number: 11135243
    Abstract: The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: October 5, 2021
    Assignee: SHED Tech Corporation
    Inventors: Minoru Ueda, Yoichi Yamada, Katsumi Ebisawa, Akihito Yamamoto, Kiyoshi Sakai, Kohki Matsubara, Hisashi Hattori, Masahiko Sugiyama, Takanori Inoue
  • Patent number: 11124770
    Abstract: A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: September 21, 2021
    Assignees: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITY
    Inventors: Hiroko Iseoka, Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima
  • Patent number: 11124767
    Abstract: Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004).
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: September 21, 2021
    Assignee: Mallinckrodt Pharmaceuticals Ireland Limited
    Inventors: David Peritt, Kim Campbell, Amy Krutsick
  • Patent number: 11116799
    Abstract: This disclosure relates generally to new methods of maintaining the expression of hepatic genes in human hepatocytes and method for maintaining the functional hepatic enzyme activity of primary hepatocytes in culture. The disclosure also encompasses new methods of deriving a population of pure hepatocytes without selecting or sorting the cells from the cultured pluripotent cells.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 14, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Srikumar Sengupta
  • Patent number: 11110260
    Abstract: Methods and devices related to the fields of skin care, hair restoration and lip care wherein the systems may be used by an individual for infusing treatment media into skin or lips for cosmetic and rejuvenation purposes, hair restoration purposes or other therapeutic purposes.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: September 7, 2021
    Assignee: Hermes Innovations, LLC
    Inventor: John H. Shadduck
  • Patent number: 11111476
    Abstract: The present invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure, including a step of culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more and 100% or less of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway and a substance inhibiting the FGF signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the “cell aggregate in which a RPE65 gene-expressing cell does not appear” thus obtained in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway and so on. According to the production method of the present invention, a ciliary marginal zone-like structure can be produced with high efficiency.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: September 7, 2021
    Assignees: Sumitomo Chemical Company, Limited, RIKEN
    Inventors: Atsushi Kuwahara, Yoshiki Sasai
  • Patent number: 11096885
    Abstract: Disclosed is to provide a composition for enhancing skin elasticity or improving skin wrinkles, which comprises a polyol as a dispersion medium, and a ginseng cell lysate dispersed in the polyol as an active ingredient. Specifically, the composition according to the present disclosure contains a polyol and all useful substances in ginseng cells dispersed in a polyol as an active ingredient, thereby exhibiting excellent skin elasticity enhancement or skin winkle improvement effects. In addition, the preparing method according to the present disclosure can effectively disperse useful substances in ginseng cells in the polyol by using a micro fluidizer, and thus can exhibit synergistic effects of useful substances in ginseng cells.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 24, 2021
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Eunjung Lee, Nok Hyun Park, Hyangtae Choi, Young Gyu Kang, Dong Hyun Kim, Yong Jin Kim
  • Patent number: 11090338
    Abstract: The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue for implantation.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: August 17, 2021
    Assignee: LifeCell Corporation
    Inventors: Aaron Barere, Jerome Connor
  • Patent number: 11090653
    Abstract: Microfluidic systems and methods to generate and analyze microcapsules comprising biological sample, such as for example, single cells, cellular contents, microspore, protoplast, are disclosed. The microcapsules comprising the biological sample can be preserved by a polymerization process that forms a hydrogel around the biological sample. The hydrogel microcapsules can be trapped in a trapping array or collected in an output reservoir and subject to one or more assays. The trapping array or the output reservoir can be disposed over a porous layer that can filter the continuous phase (e.g., oil) in which the microcapsules are dispersed in the microfluidic device. The pores of the porous layer are configured to be smaller than the size of the microcapsules to prevent the flow of the microcapsules through the porous layer.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: August 17, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Abraham P. Lee, Dohyun Lee, Yue Yun